Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA STOCK REPORT: ADMA Biologics Investors are Notified to Contact BFA Law about the Securities Fraud Investigation after Stock Drops 20%

Key Takeaway: ADMA Biologics, Inc. faces a securities fraud investigation following a significant drop in stock value. The company's stock plummeted over 20% after the unexpected resignation of its independent auditor, CohnReznick LLP, raising concerns among investors. Legal firm Bleichmar Fonti & Auld LLP has encouraged affected investors to seek further information and consider potential legal actions. This development points to serious implications for shareholder confidence and the company's standing in the market.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics' stock dropped more than 20% following the resignation of its independent auditor.
  • The investigation raises concerns about potential violations of federal securities laws.
  • The sudden drop in stock price indicates investor uncertainty and potential loss of confidence.

Full Press Release Details

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What is ADMA Biologics known for?

ADMA Biologics specializes in developing and manufacturing specialty biologics for immunodeficient patients.

Why did ADMA Biologics's stock decline?

The stock fell over 20% after the unexpected resignation of its auditor, CohnReznick LLP.

What should investors do if they lost money?

Investors can seek legal options through Bleichmar Fonti & Auld LLP for potential claims.

Is there a cost for legal representation?

No, representation is on a contingency fee basis, meaning no upfront costs for shareholders.

What accolades has BFA received?

BFA was named a Top 5 plaintiff law firm by ISS SCAS in 2023 and has notable recoveries.

Last updated: Nov 6, 2024